View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 18, 2019

Medline to buy AngioDynamics’ NAMIC portfolio for $167.5m

Medline has signed a definitive agreement to buy NAMIC's fluid management business from AngioDynamics for $167.5m.

Medline has signed a definitive agreement to buy NAMIC’s fluid management business from AngioDynamics for $167.5m.

Free Report
img

What is driving M&A activity in the MedTech space?

The COVID-19 pandemic has left an indelible mark on the MedTech landscape. Changes in how healthcare is delivered, and new treatment modalities, are creating opportunities and challenges for both new and traditional players. As companies sought out opportunities during the pandemic-driven downturn, the number and value of mergers and acquisition deals in the MedTech space increased. Companies worked to reposition themselves in the newly aligned healthcare world, but with further economic turmoil expected: will these trends be repeated? And what tech areas should firms be looking to expand their capabilities into? GlobalData’s report, “Themes driving M&A activity in the Medical Devices Sector, Q1 2022,” draws upon GlobalData’s extensive MedTech deals databases, highlighting major trends and hot themes in M&A activity. This report will assist you in:
  • Understanding value and volume trends in M&A from Q1 2018 to Q1 2022
  • Understanding regional trends in M&A activity
  • Understanding which medical device sectors are leading M&A activity, and which are lagging
  • Understanding the leading tech trends in Q1 2022 M&A activity
  • Knowing the key deals that occurred during Q1 2022
Download the full report to understand what to expect and how to align your business for success.
by GlobalData
Enter your details here to receive your free Report.

The portfolio comprises a variety of solutions for cardiac catheterisation. The acquisition includes the NAMIC brand, contrast management and closed fluid systems, guidewires, disposable transducers and interventional accessories.

AngioDynamics will also sell its manufacturing facility at Glens Falls, New York. This includes associated manufacturing, sales and marketing teams that support the NAMIC business.

AngioDynamics expects the divestiture to drive investments in other therapeutic areas such as oncology and thrombus management.

“Medline’s scale and extensive kitting operations are sure to drive more momentum for NAMIC products.”

AngioDynamics president and CEO Jim Clemmer said: “Over the past three years, we have streamlined our manufacturing operations and made significant improvements to our research and development (R&D) process, enabling us to develop high-quality, innovative medical devices for our customers.

“These actions, combined with our ongoing portfolio optimisation efforts, including today’s announced transaction with Medline, provide us with the foundation to drive sustainable and increased top-line growth and deliver high-quality new therapies that address unmet patient needs.”

AngioDynamics intends to use around $160m of net cash proceeds from the transaction to pay outstanding debt, while the remaining amount will be used for strategic investments in its existing portfolio.

Medline believes that the NAMIC business will complement its existing medical devices and supplies portfolio.

Medline CEO Charlie Mills noted: “Medline’s scale and extensive kitting operations are sure to drive more momentum for NAMIC products and deliver opportunities for efficiency for customers.”

The transaction is subject to customary closing conditions. After completion, Medline intends to continue manufacturing operations at AngioDynamics’ Glens Falls facility.

Related Companies

Free Report
img

What is driving M&A activity in the MedTech space?

The COVID-19 pandemic has left an indelible mark on the MedTech landscape. Changes in how healthcare is delivered, and new treatment modalities, are creating opportunities and challenges for both new and traditional players. As companies sought out opportunities during the pandemic-driven downturn, the number and value of mergers and acquisition deals in the MedTech space increased. Companies worked to reposition themselves in the newly aligned healthcare world, but with further economic turmoil expected: will these trends be repeated? And what tech areas should firms be looking to expand their capabilities into? GlobalData’s report, “Themes driving M&A activity in the Medical Devices Sector, Q1 2022,” draws upon GlobalData’s extensive MedTech deals databases, highlighting major trends and hot themes in M&A activity. This report will assist you in:
  • Understanding value and volume trends in M&A from Q1 2018 to Q1 2022
  • Understanding regional trends in M&A activity
  • Understanding which medical device sectors are leading M&A activity, and which are lagging
  • Understanding the leading tech trends in Q1 2022 M&A activity
  • Knowing the key deals that occurred during Q1 2022
Download the full report to understand what to expect and how to align your business for success.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network